The Avedro Corneal Cross-Linking (KXL) treatment is the first and only FDA-approved treatment available in the U.S. “We have a large community of keratoconus patients that has been anxiously awaiting FDA approval of corneal cross-linking,” explained Dr. Darcy Wolsey, cornea and refractive specialist at The Eye Institute of Utah. “We have experienced very positive results with cross-linking during clinical trials, and we are thrilled to extend this treatment option to patients in need.” Despite receiving FDA-approval for the Avedro Corneal Cross-Linking treatment in April 2016, practices across the U.S. had to wait to offer the approved KXL treatment until receiving shipments of the FDA-approved photo enhancers used for the treatment, Photrexa and Photrexa Viscous. visit this siteKeratoconus is the most common corneal dystrophy in the U.S., affecting approximately 1 in every 2,000 people. Keratoconus is a progressive eye disease that occurs when the front of the eye, called the cornea, thins and bulges into a cone-like shape. This causes significant visual distortion, progressive myopia, and may even lead to the need for corneal transplant surgery. Corneal cross-linking is considered one of the most effective treatments for slowing or halting the progression of keratoconus and preventing the need for surgical intervention. london laser eye surgeonCorneal cross-linking is a minimally invasive treatment that lasts approximately 60-90 minutes. Cross-linking uses liquid riboflavin (vitamin b2) and controlled UV light to build new collagen bonds in the cornea, which helps recover and preserve some of the cornea’s mechanical strength.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/salt-lake-city-eye-doctors-130100184.html